A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

NCT01340027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1307

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Diseases
Urinary Bladder Diseases
Urological Manifestations
Signs and Symptoms
Urinary Bladder, Overactive

Interventions

DRUG: Mirabegron
DRUG: Solifenacin succinate
DRUG: Placebo

Sponsor

Astellas Pharma Europe B.V.